Salivary evaluation in radioactive I(131) treated patients with thyroid carcinoma.

Salivary evaluation in radioactive I(131) treated patients with thyroid carcinoma.

Acta Odontol Scand. 2017 Nov 10;:1-5

Authors: Daniel FI, Lima LD, Grando LJ, Castro R, Cordeiro EAK, Dos Santos CR

Abstract
BACKGROUND AND OBJECTIVE: radioiodine treatment (I(131)) used to treat thyroid carcinomas produces side effects (sialadenitis, xerostomia, dysphagia and caries susceptibility) reflecting in a poor patient quality of life. This study aimed to evaluate the effect of I(131) on salivary function and possible oral impairment.
MATERIAL AND METHODS: Thirty-seven patients undergoing I(131) were submitted to oral examination, answer questions regarding xerostomia/hyposalivation and collect saliva at three moments (M1: 30-45 days before I(131), M2: 1-2 days after I(131) and M3: 7-10 days after treatment). Saliva was assayed for flow rate and calcium/phosphate concentrations.
RESULTS AND CONCLUSIONS: significant difference in calcium/phosphate concentration was shown between M1 and M2, with evident decrease at M2. Flow rate reduced right after treatment with 41% of patients returning to previous rate at M3 (no statistical difference). A higher number of patients related xerostomia and difficulty in swallowing food at M2. The results showed that xerostomia/hyposalivation, dysphagia and calcium/phosphate concentration decrease may be considered early radioiodine side effects.

PMID: 29125000 [PubMed - as supplied by publisher]

from Imaging via alkiviadis.1961 on Inoreader http://ift.tt/2zAs0DF